Industry ownership intelligence

Medical Devices insider conviction

Executive and director activity assessed across 83 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

Market dashboardHealthcare sectorCompany signalsFiling ledgerData API
48/100

Balanced insider tape

90/100 confidence
Level
Industry
Evidence window
Latest 90 days
Named insiders
642
Latest evidence
7 Aug 2026

Capital positioning read

Balanced insider tape

Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.

Wait for clearer clustering

Evidence in favour

  • 126 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 642 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 07 Aug 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction48Balanced insider tape
Confidence90Deep evidence
Controlled events489directional common-share events
Company breadth83represented companies
Acquisition value$26.8Mnormalized amount
Disposal value$270.7Mnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

15825 May
30901 Jun
16008 Jun
15715 Jun
7922 Jun
11129 Jun
7006 Jul
4213 Jul
3420 Jul
8227 Jul
5303 Aug
010 Aug
AcquisitionsDisposalsScore 48 · Confidence 90

Relative positioning

Industry peer map

Current score with confidence.

Pharmaceutical RetailersConviction accumulation7216 confidence Medical DistributionAccumulation bias6667 confidence Drug Manufacturers - GeneralAccumulation bias5794 confidence BiotechnologyBalanced insider tape5291 confidence Medical DevicesBalanced insider tape4890 confidence Diagnostics & ResearchDistribution bias3895 confidence Medical Care FacilitiesDistribution bias3693 confidence Health Information ServicesDistribution bias3691 confidence Medical Instruments & SuppliesDistribution bias3691 confidence Drug Manufacturers - Specialty & GenericDistribution bias3594 confidence Healthcare PlansDistribution bias3492 confidence

Directional balance

Controlled event mix

25.8%acquisition
Acquisition events
126
Disposal events
363
Net value
-$243.9M

Evidence quality

What the filings represent

Common equity1021
Equity compensation301
Options and derivatives231
Other securities10

Decision makers

Role participation

Director886
Other executive252
CEO and chair145
Finance leadership115
Other or unspecified112
Large holder53

Quality controls

Evidence usability

Normalized values
34%
Priced common share
33%
Named insiders
642
Controlled events
489

Auditable evidence

Latest Medical Devices filings

Showing 1261 to 1290 of 1563.

CODXCo-Diagnostics, Inc. Common Stock
DURENARD, EUGENEDirector
DisposalEquity compensation
Not reportedContext evidence
CODXCo-Diagnostics, Inc. Common Stock
EGAN, DWIGHT HDirector, Chief Executive Officer
DisposalEquity compensation
Not reportedContext evidence
CODXCo-Diagnostics, Inc. Common Stock
EGAN, DWIGHT HDirector, Chief Executive Officer
AcquisitionCommon equity
Not reportedContext evidence
CODXCo-Diagnostics, Inc. Common Stock
MURPHY, EDWARD L.Director
AcquisitionCommon equity
Not reportedContext evidence
CODXCo-Diagnostics, Inc. Common Stock
MURPHY, EDWARD L.Director
DisposalEquity compensation
Not reportedContext evidence
CODXCo-Diagnostics, Inc. Common Stock
NELSON, JAMES BDirector
AcquisitionCommon equity
Not reportedContext evidence
CODXCo-Diagnostics, Inc. Common Stock
NELSON, JAMES BDirector
DisposalEquity compensation
Not reportedContext evidence
CODXCo-Diagnostics, Inc. Common Stock
SERBIN, RICHARD SDirector
AcquisitionCommon equity
Not reportedContext evidence
CODXCo-Diagnostics, Inc. Common Stock
SERBIN, RICHARD SDirector
DisposalEquity compensation
Not reportedContext evidence
CODXCo-Diagnostics, Inc. Common Stock
EGAN, DWIGHT HDirector, Chief Executive Officer
DisposalCommon equity
$8.3KDirectional evidence
CODXCo-Diagnostics, Inc. Common Stock
BROWN, BRIAN LEEChief Financial Officer
DisposalCommon equity
$6.8KDirectional evidence
CODXCo-Diagnostics, Inc. Common Stock
ABBOTT, RICHARD DAVIDPresident
DisposalCommon equity
$3.4KDirectional evidence
ESTAEstablishment Labs Holdings Inc
CUSTIN, ANNDirector
AcquisitionCommon equity
Not reportedContext evidence
ESTAEstablishment Labs Holdings Inc
GILLIN, LESLIEDirector
AcquisitionCommon equity
Not reportedContext evidence
ESTAEstablishment Labs Holdings Inc
LEWIN, NICHOLAS SHERIDANDirector
AcquisitionCommon equity
Not reportedContext evidence
ESTAEstablishment Labs Holdings Inc
SCHUTTER, EDWARD JDirector
AcquisitionCommon equity
Not reportedContext evidence
ESTAEstablishment Labs Holdings Inc
SLOTKIN, BRYANDirector
AcquisitionCommon equity
Not reportedContext evidence
HYPRHyperfine Inc
DAHLDORF, JOHN TDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
HYPRHyperfine Inc
FATTORI, RUTH ADirector
AcquisitionOptions and derivatives
Not reportedContext evidence
HYPRHyperfine Inc
ROTHBERG, JONATHAN MDirector, 10% Owner
AcquisitionOptions and derivatives
Not reportedContext evidence
HYPRHyperfine Inc
WOLTERMAN, DANDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
QDELQuidel Corporation
RHOADS, ANN DDirector
AcquisitionCommon equity
Not reportedContext evidence
QDELQuidel Corporation
RHOADS, ANN DDirector
DisposalEquity compensation
Not reportedContext evidence
QDELQuidel Corporation
RHOADS, ANN DDirector
AcquisitionCommon equity
Not reportedContext evidence
QDELQuidel Corporation
RHOADS, ANN DDirector
DisposalEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
BERNARD, BETSY JDirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
BERNARD, BETSY JDirector
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
FARRELL, MICHAEL J.Director
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
FARRELL, MICHAEL J.Director
AcquisitionEquity compensation
Not reportedContext evidence
ZBHZimmer Biomet Holdings Inc
HAGEMANN, ROBERTDirector
AcquisitionEquity compensation
Not reportedContext evidence

Group-level method

Breadth before headline value

Company breadth

A sector or industry score must be supported across companies. One very large filing cannot manufacture broad conviction.

Economic duplicates

Matching company, date, side, security class, share count, and value records are consolidated for the directional calculation.

Evidence hierarchy

Priced common-share activity determines direction. Compensation and derivative records are mapped separately so ownership mechanics remain visible.

Positioning use

The score identifies where insider alignment merits research or where disposal concentration needs review. Price, trend, valuation, and portfolio risk still decide positioning.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context